—
C+
C+ The full Closelook — membership. Open the C+ overview

Smith & Nephew SNATS Inc (SNN) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Smith & Nephew SNATS Inc

SNN in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Smith & Nephew designs and sells medical devices across three areas: joint replacement and trauma implants, sports-medicine tools for minimally invasive joint surgery, and wound-care products for chronic and post-operative wounds. It supplies hospitals and surgeons in the UK, the US and other markets, and is headquartered in Watford, England.
Where it sits in the stack
Smith & Nephew sits outside our AI build-out universe; it belongs to the Healthcare sector, Medical Devices industry, and does not hold a seat in either of our indices.
Who it is priced against
The comparison the market draws is with other orthopaedic and wound-care device makers such as Stryker, given the overlap in implants and surgical tools.
Why Closelook tracks it
It carries no seat in our indices and no peer group from the diary's sort; it holds a score, but with only one module scored so far the read is still being built, and no quotes are on file.
What the diary watches
Whether demand for elective joint procedures and wound-care volumes recovers enough to lift growth across its three segments together.

Smith & Nephew SNATS Inc (SNN) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 55/100 composite (momentum 22, quality 54, valuation 74) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for SNN, from the same nightly bakes the boards use. Research diary readings, not advice.

The Street on this name 3 analyst actions on the wire · latest: price target by Berenberg, 2026-09-11

The Street on this name

Analyst actions and the latest print for SNN from the Closelook wires — third-party opinions on the record, not our readings.

  • Price target Berenberg — target 33.88 from 33.77 Target raised to $33.88 from $33.77 (+23.4% to spot) 2026-09-11
  • Downgrade Morgan Stanley — Overweight → Cautious Downgraded to Cautious from Overweight 2026-09-02
  • Initiation BTIG — at Neutral Initiated to Neutral 2026-08-31

3 actions on the analyst wire since 2026-08-13: 1 downgrade, 1 initiation, 1 target change. Analyst wire → · Earnings wire →

Who it is priced against Medical Devices · US · 8 names with week and year-to-date

Peer group

Medical Devices · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against SNN on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return trailing yield 2.81%, semi-annual · buybacks 502 m USD in FY2025

Dividends and capital return

What SNN pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 0.78 USD per share · a 2.81% yield on the 2026-09-17 close 2 distributions, paid twice a year 2026-09-17
  • Change on the year +69.3% against the prior twelve months prior twelve months 0.46 USD per share
  • Last distribution 0.48 USD per share as the price series records it, within days of the ex-date 2026-03-27
  • By calendar year 2025: 0.76 USD (partial) · 2026: 0.48 USD to date first distribution recorded in the three-year window: 2025-03-28
  • Dividends paid, FY2025 330 m USD 3% of earnings
  • Buybacks, FY2025 502 m USD 4.3% of today's market value
  • Share count −0.4% in FY2025 43 m USD of stock-based compensation in the year
  • Capital returned 832 m USD · 98% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sector × region Health care in US: +0.7% week · +0.4% month · +10.2% quarter · +6.7% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-16
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Smith & Nephew SNATS Inc (SNN)?

Smith & Nephew SNATS Inc trades as SNN on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-18.

Is SNN in a Closelook index?

Not currently — Smith & Nephew SNATS Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

What is Smith & Nephew SNATS Inc's Closelook composite score?

55 out of 100, with momentum 22, quality 54 and valuation 74 sub-scores, as of 2026-09-18. Scores are Closelook's own research readings, not ratings or investment advice.

Where does SNN trade against its moving averages?

Downtrend stack: Trades -6.8% vs the 50-day and -12.1% vs the 200-day average, 24.8% below the 52-week high and +2% off the 52-week low. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Smith & Nephew SNATS Inc do?

Smith & Nephew designs and sells medical devices across three areas: joint replacement and trauma implants, sports-medicine tools for minimally invasive joint surgery, and wound-care products for chronic and post-operative wounds. It supplies hospitals and surgeons in the UK, the US and other markets, and is headquartered in Watford, England. The comparison the market draws is with other orthopaedic and wound-care device makers such as Stryker, given the overlap in implants and surgical tools.

Where does Smith & Nephew SNATS Inc sit in the AI build-out?

Smith & Nephew sits outside our AI build-out universe; it belongs to the Healthcare sector, Medical Devices industry, and does not hold a seat in either of our indices. It carries no seat in our indices and no peer group from the diary's sort; it holds a score, but with only one module scored so far the read is still being built, and no quotes are on file.

Does Smith & Nephew SNATS Inc pay a dividend?

Smith & Nephew SNATS Inc has paid 0.78 USD per share over the last twelve months, paid twice a year, a trailing yield of 2.81% on the 2026-09-17 close; the last distribution recorded in the price series was 0.48 USD on 2026-03-27. In fiscal 2025 the company paid 330 m USD in dividends and bought back 502 m USD of its own shares, 98% of that year’s free cash flow. The share count fell 0.4% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Smith & Nephew SNATS Inc recently?

The most recent analyst action on Smith & Nephew SNATS Inc on the Closelook wire is a price target by Berenberg on 2026-09-11 (target 33.88 from 33.77). 3 actions on the analyst wire since 2026-08-13: 1 downgrade, 1 initiation, 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelook readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for SNN, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Medical Devices. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.